Pharmacoeconomic aspects of bronchial asthma therapy: real clinical practice

Abstract

According to official statistics, over 1.5 million people have BA in the Russian Federation. Direct costs associated with the treatment of BA in the Russian Federation amount to 8.5 billion rubles. The socioeconomic burden of BA put on society, along with temporary and permanent disability, is caused by not only direct, but also indirect costs, as well as costs associated with payments for temporary disability, which leads to a decrease in GDP and GRP (internal gross regional product). The pharmacoeconomic comparison of two alternative drug technologies in the studied groups showed a reasonable opportunity to transfer patients to the drugs that have alternatives produced within the country, confirming that the cost per efficiency unit in using Formisonide-Native and SalticasoneNative is lower than that of drugs produced by a foreign pharmaceutical company (Symbicort Turbuhaler and Seretide Multidisk)

Keywords

• bronchial asthma
• pharmacoeconomic analysis
• budesonide
• formoterol
• salmeterol
• fluticasone
• formisonide-native
• salticasone-nativ